Clinical trials: Hepatitis C Infections
Hepatitis C, Chronic
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4
This 6-arm study will assess the efficacy and safety of RO5024048 (R7128) in combination with the approved doses of Pegasys (180micrograms sc weekly) + Copegus (1000/1200mg po daily) (SOC), versus SOC in treatment-naive patients…
- Trial name
- NCT00869661
- Testing
- Copegus, Pegasys, RO5024048
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 413 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus Infection
Safety and Efficacy Study in Hepatitis C Patients With PHN121
To evaluate the safety, tolerability and efficacy of escalating dose of PHN121 when administered orally in non-responder hepatitis C genotype 1 patients
- Trial name
- ENCHAMP (NCT01052090)
- Testing
- PHN121
- Where
- 2 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- PhytoHealth Corporation
Hepatitis C Virus
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a…
- Trial name
- PEDESTAL (NCT01598090)
- Testing
- Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin
- Where
- 104 sites in United States, Austria and 13 more
- Volunteers
- 881 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with…
- Trial name
- NCT01356160
- Testing
- GS-5885, GS-9451, peginterferon alfa-2a
- Where
- 23 sites in United States, Australia and 1 more
- Volunteers
- 351 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
This study will investigate safety, antiviral activity, and pharmacokinetics of BI 201335 NA in HCV genotype 1 infected patients treated for 14 days monotherapy followed by BI 201335 NA combination therapy with PegIFN/RBV for an…
- Trial name
- NCT00793793
- Testing
- BI201335
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 96 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C
Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
The purpose of this study is to determine whether multiple doses of darunavir/ritonavir or lopinavir/ritonavir affect the pharmacokinetics of daclatasvir in healthy participants.
- Trial name
- NCT02159352
- Testing
- Daclatasvir, Darunavir, Ritonavir
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic, Nonadherence, Patient
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
This study evaluates the ability of digital medicines, Proteus Discover, to promote adherence and thus achieving a cure for hepatitis C in patients at high risk for not adhering to their hepatitis therapy.
- Trial name
- DASH (NCT03164902)
- Testing
- Digital Medicine
- Where
- 16 sites in United States
- Volunteers
- 253 people
- Sponsor
- Proteus Digital Health, Inc.
Hepatitis C
An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection
The purpose of this study is to evaluate the efficacy of simeprevir in combination with sofosbuvir for 8 or 12 weeks versus a historical control, with respect to the percentage of participants with sustained virologic response at…
- Trial name
- NCT02278419
- Testing
- Simeprevir, Sofosbuvir
- Where
- 2 sites in Egypt
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Hepatitis C
Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects
The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of the co-administration of VCH-222 and telaprevir in healthy subjects.
- Trial name
- NCT00958152
- Testing
- VCH-222, telaprevir
- Where
- New Zealand
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
HIV Coinfection
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.
- Trial name
- NCT01327547
- Testing
- Maraviroc
- Where
- 48 sites in United States, Czechia and 7 more
- Volunteers
- 138 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis C Virus
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive…
- Trial name
- NCT01851330
- Testing
- LDV/SOF, RBV
- Where
- 52 sites in United States
- Volunteers
- 647 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus (HCV)
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
This was a Phase 3b, open-label, non-randomized, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1 - 6 infection…
- Trial name
- EXPEDITION-5 (NCT03069365)
- Testing
- Glecaprevir/pibrentasvir
- Where
- 38 sites in United States, Canada and 8 more
- Volunteers
- 101 people
- Sponsor
- AbbVie
Chronic Hepatitis C
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment.
- Trial name
- VISER2 (NCT00093093)
- Testing
- Viramidine, Ribavirin, pegylated interferon alfa-2a
- Where
- 100 sites in United States, Argentina and 10 more
- Volunteers
- 900 people
- Sponsor
- Bausch Health Americas, Inc.
Hepatitis C
Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)
This is a study comparing grazoprevir (MK-5172) plus elbasvir (MK-8742) treatment with sofosbuvir (SOF) plus Pegylated Interferon plus Ribavirin (RBV) [PR] treatment in treatment-naïve and prior PR treatment failure participants…
- Trial name
- NCT02358044
- Testing
- Sofosbuvir, PegIntron, Ribavirin
- Volunteers
- 257 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C
A Phase 2, randomized, double-blind, parallel design trial of two doses of mitoquinone mesylate (MitoQ) and of placebo in patients with chronic Hepatitis C.
- Trial name
- NCT00433108
- Testing
- Mitoquinone mesylate (MitoQ)
- Where
- 2 sites in New Zealand
- Volunteers
- 30 people
- Sponsor
- Antipodean Pharmaceuticals, Inc.
Hepatitis C
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis…
- Trial name
- NCT00128271
- Testing
- Bavituximab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Peregrine Pharmaceuticals
Hepatitis C
Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic…
- Trial name
- NCT01909804
- Testing
- SOF, VEL, RBV
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 323 people
- Sponsor
- Gilead Sciences
Hepatitis C, Cirrhosis
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated chronic hepatitis C virus (HCV) infection.
- Conditions
- Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
- Trial name
- NCT01687257
- Testing
- SOF, RBV
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C, Decompensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.
- Conditions
- Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus
- Trial name
- TURQUOISE-CPB (NCT02219477)
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 36 people
- Sponsor
- AbbVie
Hepatitis C Infection
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)
This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who…
- Trial name
- NCT02105701
- Testing
- Grazoprevir + Elbasvir, Ribavirin
- Volunteers
- 420 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.